Palatin Technologies, Inc. (PTN) Q3 2023 Earnings Call Transcript

Palatin Applied sciences, Inc. (NYSE:PTN) Q3 2023 Earnings Convention Name Might 16, 2023 11:00 AM ET

Firm Contributors

Carl Spana – President and Chief Govt Officer

Steve Wills – Govt Vice President, Chief Monetary Officer and Chief Working Officer

Convention Name Contributors

Joe Pantginis – H.C. Wainwright

Michael Higgins – Ladenburg Thalmann

Operator

Greetings. Welcome to Palatin’s Third Quarter Fiscal 12 months 2023 Working Outcomes Convention Name. [Operator Instructions] As a reminder, this convention is being recorded. Earlier than we start our remarks, I wish to remind you that statements made by Palatin are usually not historic info and could also be forward-looking statements. These statements are based mostly on assumptions which will or could not show to be correct and that the precise outcomes could differ materially from these anticipated as a result of number of dangers and uncertainties mentioned within the firm’s most up-to-date filings with the Securities and Change Fee. Please take into account such dangers and uncertainties rigorously in evaluating these forward-looking statements by Palatin’s prospects.

Now I wish to flip the decision over to Dr. Carl Spana, President and Chief Govt Officer of Palatin. Please go forward.

Carl Spana

Thanks. Good morning and welcome to the Palatin third quarter fiscal 2023 name. I’m Dr. Carl Spana, CEO and President of Palatin. With me on the decision in the present day is Steve Wills, Palatin’s Govt Vice President, Chief Monetary Officer and Chief Working Officer. I’ll now flip the decision over to Steve, and he’ll give the monetary and working replace. Steve?

Steve Wills

Thanks, Carl. Good day, everybody. Concerning monetary highlights, I’ll begin with Vyleesi. Vyleesi is our FDA-approved business product for pre-menopausal ladies with hypoactive sexual want dysfunction, or HSDD. The objective of the Vyleesi program is to reveal business product worth within the market with an goal of licensing the U.S. rights to a dedicated ladies’s well being care firm.

Back To Top